AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0

Sitasentro-M50 Tablet

Prescription Icon
Prescription Required

Marketer

Sentro Pharma & Healthcare

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Sitasentro-M50 Tablet

Combiflor-DM50 is a dual-action tablet managing elevated blood glucose in type 2 diabetes. This mitigates severe diabetic complications like nephropathy and visual impairment, potentially lowering cardiovascular event risk. Combiflor-DM50 might be prescribed independently or adjunctively with other antidiabetic agents. Optimal efficacy requires concurrent adherence to a balanced diet and regular physical activity. Dosage is individualized based on your health status, glycemic control, and concomitant medications. Consuming it with meals minimizes gastrointestinal distress. Consistent daily dosing at the same time maximizes therapeutic benefit; discontinuation should only occur under physician guidance. Maintaining your prescribed diet and exercise regimen is crucial for diabetes management; lifestyle significantly influences glycemic control. Common adverse effects include diarrhea, nausea, emesis, dyspepsia, cephalalgia, and pharyngitis. Hypoglycemia is a potential side effect, particularly when combined with insulin or sulfonylureas; appropriate management strategies are essential. This medication isn't universally suitable. Prior to commencement, inform your doctor of any history of renal, hepatic, or cardiac disease, pancreatic issues, or significant alcohol consumption. Pregnant or lactating individuals should seek medical counsel. Potential drug interactions necessitate informing your physician of all current medications to ensure safety. Alcohol should be minimized due to its hypoglycemic effect. Your physician will monitor renal function and blood glucose levels throughout therapy.

Uses of Sitasentro-M50 Tablet

Managing type 2 diabetes

Major Benefits of Sitasentro-M50 Tablet:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Sitasentro-M50 Tablets should be administered with a meal.

Common Side effects of Sitasentro-M50 Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitasentro-M50 Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for Sitasentro-M50 Tablets. Ingest the tablets whole; do not crush, chew, or break them before swallowing. Consume this medication with food.

How Sitasentro-M50 Tablet works:

Sitasentro-M50 tablets contain sitagliptin and metformin, working synergistically to manage blood glucose. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and reduces hepatic glucose output. Metformin, a biguanide, decreases liver glucose production, slows intestinal glucose absorption, and increases insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol alongside Sitasentro-M50 Tablet is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Sitasentro-M50 Tablet during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Nursing mothers should likely avoid Sitasentro-M50 tablets. Preliminary human studies indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Exercise caution when administering Sitasentro-M50 Tablets to individuals with impaired kidney function; dosage modification may be necessary. Consult a physician for guidance. Sitasentro-M50 Tablets are contraindicated in patients exhibiting severe renal impairment. Routine monitoring of renal function is recommended during treatment.

LiverLiverUNSAFE

The use of Sitasentro-M50 Tablets is likely inadvisable for individuals with hepatic impairment and should be omitted. Seek medical counsel.

What if you forget to take Sitasentro-M50 Tablet :

Should you forget a Sitasentro-M50 Tablet dose, administer it immediately. However, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Sitasentro-M50 Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Sitasentro-M50 Tablet

Sitasentro-M50 Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18 years old.
Prolonged Sitasentro-M50 Tablet use can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 intake is recommended by some researchers.
Sitasentro-M50 Tablet may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Sitasentro-M50 Tablets are contraindicated in patients with known allergies to any ingredient or excipient. This medication should also be avoided by individuals with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitasentro-M50 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitagliptin/Metformin (like Sitasentro-M50) can rarely cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This risk is heightened in patients with kidney disease, the elderly, or those consuming significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin immediately and seek urgent medical attention.
Sitasentro-M50 Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Sitasentro-M50 Tablet may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infection. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Sitasentro-M50 Tablets are contraindicated in patients with known hypersensitivity to any ingredient. Avoid use in patients with severe renal or hepatic impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitasentro-M50 Tablet and alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (Sitasentro-M50) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis or MALA). This rare side effect necessitates avoiding its use in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin immediately and seek medical attention.
Prolonged Sitasentro-M50 Tablet use can lead to vitamin B12 deficiency by impairing its absorption in the stomach. This deficiency may cause anemia and neurological issues, manifesting as tingling, numbness in extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Sitasentro-M50 Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Sitasentro-M50 Tablet may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Sitasentro-M50 Tablets are contraindicated in patients with hypersensitivity to any ingredient. Avoid use in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitasentro-M50 Tablet and alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin + Metformin (like Sitasentro-M50) can rarely cause lactic acidosis (MALA), a serious medical emergency resulting from excessive blood lactic acid. This risk is heightened in patients with kidney disease, the elderly, and heavy alcohol users, thus making it contraindicated in these groups. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Sitasentro-M50 Tablet use can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. Preventive measures, suggested by some researchers, include annual supplemental vitamin B12 intake.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it's kept out of reach of children, pets, and others.
Sitasentro-M50 Tablet
168
MRP 194
13% off